The need for core outcome sets (COS) in atopic dermatitis (AD) is supported by the international Harmonising Outcome Measures for Eczema (HOME) group’s work.
Researchers sought to evaluate results from adults with moderate to severe atopic dermatitis who are treated with abrocitinib after being treated with dupilumab.
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
To better standardize the symptoms and signs of diaper dermatitis, investigators reviewed the literature for all descriptive words used to define diaper dermatitis.
